Alkem Laboratories Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Alkem and IIT Bombay announce strategic collaboration to set up advanced research centre for immuno-therapeutics and regenerative medicines".
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Foundation, the CSR arm of Alkem Laboratories, has partnered with IIT Bombay to set up India's first dedicated research centre for immuno-therapeutics and regenerative medicines on the IIT Bombay campus. Alkem Foundation will fund the 'Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines' by contributing 20-25% of its cumulative CSR obligations spread over seven years. The centre will work on advanced areas such as gene editing, biomaterials, and cell and gene therapy, while also serving as a training and incubation hub for clinician-scientists and biotech entrepreneurs. The collaboration is described as the first industry-academia partnership in India for this field initiated through the CSR route, combining Alkem's pharma expertise with IIT Bombay's research capabilities and global academic mentors.
Since this is a CSR-funded initiative, there is no direct commercial investment or immediate financial impact on shareholders. However, it may strengthen Alkem's long-term innovation pipeline, brand reputation, and talent access in high-precision medicine, which could support future growth in chronic and advanced therapy segments.